RAP 0.00% 20.5¢ raptor resources limited

Ann: AstraZeneca to use new ResApp software in clinical study, page-25

  1. 2,574 Posts.
    lightbulb Created with Sketch. 4962
    Very interesting, doing business now with a major Japanese Global Pharmaceutical Company although the initial income is unknown and most likely not material at this stage it is a major step forward from them issuing a free licence agreement as per the other arrangement in the Queensland clinic... now this is turning into a business rather than a charity case.

    Ok so this study goes for 2 years and the number of test subjects at this stage is unknown but for them to have statistically significant results you would assume at least they would have a decent amount of test subjects.. anyway it's not this study that's got me excited because it's another long two year wait before results would be even published and could lead absolutely nowhere just like Sanofi it's the improvement in the technology that ResApp will be looking to integrate into its existing Proprietary technology and amongst other gadgets and gizmos that has me bard up..

    "The application is the result of over 12 months development and uses the company’s patent protected technology to identify coughs from background noises in everyday settings. The
    application records the number of coughs from a patient and uploads the count with a time and date stamp to allow researchers and healthcare professionals to monitor patients in real time. "
    "Cough frequency is a key factor in respiratory disease progression and management. Traditionally, the only ways to measure the occurrences is by subjective self-reporting or manually
    listening to audio recordings. These methods are labour intensive, not cost effective and fraught with inaccuracy. The cough counting application was developed to deliver patients and healthcare providers more accurate and reliable analysis for disease monitoring."

    This is an excellent technical advancement, great achievement!


    "ResApp is confident that the initial development stages with AstraZeneca and the clinical trial will deliver insights for future product applications. The company is actively exploring opportunities to integrate the technology into a range of hardware devices and existing products, including
    smart devices. Discussions with large industry partners are underway and ResApp is confident further developments will be made in the coming months."

    Licking my lips from this statement, yummy

    Wow! Can't wait for Android integration and an EU deal that's what's really going to get this puppy fired up, hopefully the next announcements to come...

    Cheers

    Red bar
    Last edited by Red bar: 22/10/20
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.